Efficacy of Albumin-Bound Paclitaxel Combined with Nedaplatin in Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma: A Single-Center Retrospective Observational Study
March 2023
in “
Medicine
”
Studysummary This study found that albumin-bound paclitaxel combined with nedaplatin shows promise as neoadjuvant therapy for esophageal squamous cell carcinoma, achieving a high complete response rate with manageable side effects.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
This single-center retrospective observational study assessed the efficacy and safety of albumin-bound paclitaxel combined with nedaplatin as neoadjuvant therapy for esophageal squamous cell carcinoma (ESCC) in 41 patients. The study achieved a 100% R0 resection rate, with a 17.1% pathological complete response (pCR) rate and 51.2% of patients experiencing tumor downstaging. Common adverse events included hematologic toxicity (24.4%) and gastrointestinal reactions (17.1%), with no grade 4 or higher events. The results indicate that this combination therapy is effective and well-tolerated, offering a potential alternative to more toxic regimens, though the study's small sample size and lack of a control group are limitations.
